150 related articles for article (PubMed ID: 31374307)
1. Increased mortality in patients with porphyria cutanea tarda-A nationwide cohort study.
Christiansen AL; Brock A; Bygum A; Rasmussen LM; Jepsen P
J Am Acad Dermatol; 2020 Sep; 83(3):817-823. PubMed ID: 31374307
[TBL] [Abstract][Full Text] [Related]
2. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study.
Baravelli CM; Sandberg S; Aarsand AK; Tollånes MC
Orphanet J Rare Dis; 2019 Apr; 14(1):77. PubMed ID: 30944007
[TBL] [Abstract][Full Text] [Related]
3. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden.
Linet MS; Gridley G; Nyrén O; Mellemkjaer L; Olsen JH; Keehn S; Adami HO; Fraumeni JF
Am J Epidemiol; 1999 Jun; 149(11):1010-5. PubMed ID: 10355376
[TBL] [Abstract][Full Text] [Related]
4. Porphyria cutanea tarda and patterns of long-term sick leave and disability pension: a 24-year nationwide matched-cohort study.
Baravelli CM; Aarsand AK; Sandberg S; Tollånes MC
Orphanet J Rare Dis; 2022 Feb; 17(1):72. PubMed ID: 35193623
[TBL] [Abstract][Full Text] [Related]
5. [Role of the hemochromatosis gene in prophyria cutanea tarda. Prospective study of 56 cases].
Skowron F; Bérard F; Grézard P; Wolf F; Morel Y; Perrot H
Ann Dermatol Venereol; 2001 May; 128(5):600-4. PubMed ID: 11427792
[TBL] [Abstract][Full Text] [Related]
6. Association of porphyria cutanea tarda with hereditary hemochromatosis.
Mehrany K; Drage LA; Brandhagen DJ; Pittelkow MR
J Am Acad Dermatol; 2004 Aug; 51(2):205-11. PubMed ID: 15280838
[TBL] [Abstract][Full Text] [Related]
7. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease.
Fracanzani AL; Taioli E; Sampietro M; Fatta E; Bertelli C; Fiorelli G; Fargion S
J Hepatol; 2001 Oct; 35(4):498-503. PubMed ID: 11682034
[TBL] [Abstract][Full Text] [Related]
8. [Significance and prevalence of the C282Y gene mutation of primary hemochromatosis in the pathogenesis of pophyria cutanea tarda].
Malina L; Zd'árský E; Dandová S; Michalíková H; Cerná M; Cimburová M
Cas Lek Cesk; 2000 Nov; 139(23):728-30. PubMed ID: 11191743
[TBL] [Abstract][Full Text] [Related]
9. Porphyria cutanea tarda.
Bleasel NR; Varigos GA
Australas J Dermatol; 2000 Nov; 41(4):197-206; quiz 207-8. PubMed ID: 11105361
[TBL] [Abstract][Full Text] [Related]
10. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.
Bulaj ZJ; Phillips JD; Ajioka RS; Franklin MR; Griffen LM; Guinee DJ; Edwards CQ; Kushner JP
Blood; 2000 Mar; 95(5):1565-71. PubMed ID: 10688809
[TBL] [Abstract][Full Text] [Related]
11. Nationwide Assessment of Cause-Specific Mortality in Patients with Rosacea: A Cohort Study in Denmark.
Egeberg A; Fowler JF; Gislason GH; Thyssen JP
Am J Clin Dermatol; 2016 Dec; 17(6):673-679. PubMed ID: 27480418
[TBL] [Abstract][Full Text] [Related]
12. Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients.
Muñoz-Santos C; Guilabert A; Moreno N; To-Figueras J; Badenas C; Darwich E; Herrero C
Medicine (Baltimore); 2010 Mar; 89(2):69-74. PubMed ID: 20517178
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of hepatitis C virus type 1b in Italian patients with Porphyria cutanea tarda.
Sampietro M; Fracanzani AL; Corbetta N; Amato M; Mattioli M; Molteni V; Fiorelli G; Fargion S
Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):543-7. PubMed ID: 9513830
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study.
Andersen J; Thomsen J; Enes ÅR; Sandberg S; Aarsand AK
Health Qual Life Outcomes; 2020 Mar; 18(1):84. PubMed ID: 32228630
[TBL] [Abstract][Full Text] [Related]
15. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda.
Brady JJ; Jackson HA; Roberts AG; Morgan RR; Whatley SD; Rowlands GL; Darby C; Shudell E; Watson R; Paiker J; Worwood MW; Elder GH
J Invest Dermatol; 2000 Nov; 115(5):868-74. PubMed ID: 11069625
[TBL] [Abstract][Full Text] [Related]
16. [Porphyria cutanea tarda: the benefit of additional diagnostics].
Vossen AR; Boesten LS; Siersema PD; Nellen RG
Ned Tijdschr Geneeskd; 2016; 160():A9166. PubMed ID: 26840933
[TBL] [Abstract][Full Text] [Related]
17. Experience in management of porphyria cutanea tarda in a tertiary referral Brazilian hospital from 2002 to 2017.
Cabezas Arteaga JE; Vieira FMJ; Silva Dos Reis VM
Int J Dermatol; 2019 Aug; 58(8):925-932. PubMed ID: 30773624
[TBL] [Abstract][Full Text] [Related]
18. Familial and sporadic porphyria cutanea tarda: clinical, biochemical and genetic features with emphasis on iron status.
Bygum A; Christiansen L; Petersen NE; Hørder M; Thomsen K; Brandrup F
Acta Derm Venereol; 2003; 83(2):115-20. PubMed ID: 12735639
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda.
Gisbert JP; García-Buey L; Alonso A; Rubio S; Hernández A; Pajares JM; García-Díez A; Moreno-Otero R
Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):689-92. PubMed ID: 15201583
[TBL] [Abstract][Full Text] [Related]
20. Autoimmunity and HCV infection in porphyria cutanea tarda: a controlled study.
Stölzel U; Schuppan D; Tillmann HL; Manns MP; Tannapfel A; Doss MO; Zimmer T; Köstler E
Cell Mol Biol (Noisy-le-grand); 2002 Feb; 48(1):43-7. PubMed ID: 11929046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
